<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><submitter>Liu J</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>The increasing burden of non-alcoholic fatty liver disease (NAFLD) worldwide imposes an emerging public health issue. We perform the current study to estimate the global prevalence, incidence, disease progression, and clinical outcomes of NAFLD.&lt;h4>Methods&lt;/h4>A systematic search was conducted in five databases that screened articles in English language published from January 2000 to December 2021. NAFLD prevalence, incidence, rate of disease progression, and outcomes were calculated with the DerSimonian-Laird random effects model with arcsine transformation.&lt;h4>Results&lt;/h4>Our search identified 59,156 records, of which 578 studies fulfilled our inclusion criteria. The overall prevalence of NAFLD was 29.38% (95% confidence interval [CI] 28.09-30.69) regardless of the dia</pubmed_abstract><journal>Chinese medical journal</journal><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9509027</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Estimating global prevalence, incidence, and outcomes of non-alcoholic fatty liver disease from 2000 to 2021: systematic review and meta-analysis.</pubmed_title><pmcid>PMC9509027</pmcid><pubmed_authors>Ni Y</pubmed_authors><pubmed_authors>Liu Y</pubmed_authors><pubmed_authors>Liu J</pubmed_authors><pubmed_authors>Li Z</pubmed_authors><pubmed_authors>Fu X</pubmed_authors><pubmed_authors>Tian Y</pubmed_authors><pubmed_authors>Yao M</pubmed_authors><pubmed_authors>Mu C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Estimating global prevalence, incidence, and outcomes of non-alcoholic fatty liver disease from 2000 to 2021: systematic review and meta-analysis.</name><description>&lt;h4>Background&lt;/h4>The increasing burden of non-alcoholic fatty liver disease (NAFLD) worldwide imposes an emerging public health issue. We perform the current study to estimate the global prevalence, incidence, disease progression, and clinical outcomes of NAFLD.&lt;h4>Methods&lt;/h4>A systematic search was conducted in five databases that screened articles in English language published from January 2000 to December 2021. NAFLD prevalence, incidence, rate of disease progression, and outcomes were calculated with the DerSimonian-Laird random effects model with arcsine transformation.&lt;h4>Results&lt;/h4>Our search identified 59,156 records, of which 578 studies fulfilled our inclusion criteria. The overall prevalence of NAFLD was 29.38% (95% confidence interval [CI] 28.09-30.69) regardless of the dia</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Aug</publication><modification>2025-04-18T20:57:42.23Z</modification><creation>2025-04-07T08:59:29.087Z</creation></dates><accession>S-EPMC9509027</accession><cross_references><pubmed>36070463</pubmed><doi>10.1097/CM9.0000000000002277</doi></cross_references></HashMap>